Market Overview:
The global uterine fibroids treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of uterine fibroids, technological advancements in the field of uterine fibroid treatment, and rising awareness about available treatments for uterine fibroids. Based on type, the global uterine fibroid treatment market is segmented into endometrial ablation, MRI guided procedures, hysterectomy, myomectomy, Uterine artery embolization (UAE), radiofrequency ablation (RFA), and others. The endometrial ablation segment accounted for the largest share of the global market in 2017 owing to its high adoption rate across hospitals and ambulatory surgical centers. Based on application, the global uterus Fibroid Treatment Market is segmented into hospitals, ambulatory surgical centers (ASCs), and others. Hospitals accounted for a majority share of the overall market in 2017 due to increased use of minimally invasive procedures such as UAE and RFA in this setting.
Product Definition:
Uterine fibroids are benign (noncancerous) tumors that grow in the uterus. They are the most common type of tumor found in women and can occur at any age, but are most common after 30. Uterine fibroids treatment is important because these tumors can cause pain, heavy menstrual bleeding, and other problems. Treatment options include medicines, surgery, or a combination of both.
Endometrial Ablation:
Endometrial ablation is a procedure to remove the endometrium, a thin layer of tissue that lines the uterus. The endometrium has two functions: it provides an immune defense and helps regulate menstrual flow. When excessive bleeding occurs, the endometrial ablation market gains popularity as it can be used for heavy menstrual bleeding or menorrhagia.
MRI Guided Procedures:
Magnetic Resonance Imaging Guided (MR Guided) procedures are used in the treatment of uterine fibroids. These procedures use magnetic fields and radio waves to destroy tissue that holds a tumor. This procedure is done by an interventional radiologist, who inserts a magnetic field into the body using very small needles, called catheters. The radio waves cause damage to the tissues without affecting other parts of the body including organs and bones.
Application Insights:
Based on application, the global uterine fibroids treatment market is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to increasing awareness about available treatments and growing availability of advanced healthcare facilities. Furthermore, an increase in prevalence rates of heavy menstrual bleeding is boosting demand for these procedures at hospitals across the globe.
Uterine fibroids are typically found during a routine pelvic examination or diagnostic ultrasound scan performed by a gynecologist to identify any abnormalities present within the uterus. These growths may cause symptoms such as heavy bleeding or pain during sex which require medical attention right away as they may signal more serious conditions such as cancerous tumors or pregnancy complications. Thus rising number of women diagnosed with uterine fibroids & other related disorders is contributing towards high adoption rate among patients seeking treatment for this condition at hospitals worldwide.
Regional Analysis:
North America dominated the global uterine fibroids treatment market in 2017. This can be attributed to the availability of advanced technologies, higher adoption rate of new technologies, and presence of well-established healthcare facilities in this region. In addition, increasing government initiatives for raising awareness levels about uterine fibroids is also expected to fuel growth during the forecast period. For instance, Uterine Fibroid Awareness (UFA) Month is organized every year in October that focuses on educating women about different treatments available for treating uterine fibroids as well as raise awareness among health professionals and general public regarding these disorders.
Growth Factors:
- Increasing incidence of uterine fibroids
- Growing awareness about the available treatment options for uterine fibroids
- Rising demand for minimally invasive procedures for uterine fibroids treatment
- Technological advancements in the field of uterine fibroid treatment
- Availability of government funding and insurance coverage for uterine fibroid treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Uterine Fibroids Treatment Market Research Report
By Type
Endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization, Radiofrequency Ablation, Others
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
Blue Endo, Boston Scientific Corporation, Cooper Surgical, Acessa Health, Inc., Karl Storz, LiNA Medical, Merit Medical Systems, Olympus Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Uterine Fibroids Treatment Market Report Segments:
The global Uterine Fibroids Treatment market is segmented on the basis of:
Types
Endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization, Radiofrequency Ablation, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Blue Endo
- Boston Scientific Corporation
- Cooper Surgical
- Acessa Health, Inc.
- Karl Storz
- LiNA Medical
- Merit Medical Systems
- Olympus Corporation
Highlights of The Uterine Fibroids Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Endometrial Ablation
- MRI Guided Procedures
- Hysterectomy
- Myomectomy
- Uterine Artery Embolization
- Radiofrequency Ablation
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Uterine Fibroids Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Uterine fibroids are benign tumors that grow in the uterus. They can cause pain, heavy periods, and difficulty getting pregnant. Treatment options include surgery, medication, or a combination of both.
Some of the key players operating in the uterine fibroids treatment market are Blue Endo, Boston Scientific Corporation, Cooper Surgical, Acessa Health, Inc., Karl Storz, LiNA Medical, Merit Medical Systems, Olympus Corporation.
The uterine fibroids treatment market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Uterine Fibroids Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Uterine Fibroids Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Uterine Fibroids Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Uterine Fibroids Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Uterine Fibroids Treatment Market Size & Forecast, 2018-2028
4.5.1 Uterine Fibroids Treatment Market Size and Y-o-Y Growth
4.5.2 Uterine Fibroids Treatment Market Absolute $ Opportunity
Chapter 5 Global Uterine Fibroids Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Uterine Fibroids Treatment Market Size Forecast by Type
5.2.1 Endometrial Ablation
5.2.2 MRI Guided Procedures
5.2.3 Hysterectomy
5.2.4 Myomectomy
5.2.5 Uterine Artery Embolization
5.2.6 Radiofrequency Ablation
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Uterine Fibroids Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Uterine Fibroids Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Uterine Fibroids Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Uterine Fibroids Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Uterine Fibroids Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Uterine Fibroids Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Uterine Fibroids Treatment Market Size Forecast by Type
9.6.1 Endometrial Ablation
9.6.2 MRI Guided Procedures
9.6.3 Hysterectomy
9.6.4 Myomectomy
9.6.5 Uterine Artery Embolization
9.6.6 Radiofrequency Ablation
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Uterine Fibroids Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Uterine Fibroids Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Uterine Fibroids Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Uterine Fibroids Treatment Market Size Forecast by Type
10.6.1 Endometrial Ablation
10.6.2 MRI Guided Procedures
10.6.3 Hysterectomy
10.6.4 Myomectomy
10.6.5 Uterine Artery Embolization
10.6.6 Radiofrequency Ablation
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Uterine Fibroids Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Uterine Fibroids Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Uterine Fibroids Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Uterine Fibroids Treatment Market Size Forecast by Type
11.6.1 Endometrial Ablation
11.6.2 MRI Guided Procedures
11.6.3 Hysterectomy
11.6.4 Myomectomy
11.6.5 Uterine Artery Embolization
11.6.6 Radiofrequency Ablation
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Uterine Fibroids Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Uterine Fibroids Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Uterine Fibroids Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Uterine Fibroids Treatment Market Size Forecast by Type
12.6.1 Endometrial Ablation
12.6.2 MRI Guided Procedures
12.6.3 Hysterectomy
12.6.4 Myomectomy
12.6.5 Uterine Artery Embolization
12.6.6 Radiofrequency Ablation
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Uterine Fibroids Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Uterine Fibroids Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Uterine Fibroids Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Uterine Fibroids Treatment Market Size Forecast by Type
13.6.1 Endometrial Ablation
13.6.2 MRI Guided Procedures
13.6.3 Hysterectomy
13.6.4 Myomectomy
13.6.5 Uterine Artery Embolization
13.6.6 Radiofrequency Ablation
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Uterine Fibroids Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Uterine Fibroids Treatment Market: Competitive Dashboard
14.2 Global Uterine Fibroids Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Blue Endo
14.3.2 Boston Scientific Corporation
14.3.3 Cooper Surgical
14.3.4 Acessa Health, Inc.
14.3.5 Karl Storz
14.3.6 LiNA Medical
14.3.7 Merit Medical Systems
14.3.8 Olympus Corporation
